Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
The Integrity Council for the Voluntary Carbon Market issued some new guidelines on what types of carbon credits it can rubber-stamp.
Uber returned to profitability in the second quarter, bucking macroeconomic trends and proving it can diversify its revenue streams.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
WW announced on Thursday that it will be laying off employees and cutting costs to the tune of $100 million per year.
Carvana posted stellar results in its latest earnings call, leaving many analysts to wonder if this may be the start of something new.
“Any potential cost savings based off a vehicle’s lower-than-average carbon footprint could influence more price-conscious consumers.”
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Uber announced a new partnership with BYD to get 100,000 of its drivers into the company’s electric vehicles.
AI-powered search engine startup Perplexity announced a revenue-sharing program on Tuesday with a handful of media companies.
Suppliers are upset Temu is swapping to a more Amazon-esque supplier model and trying to drive prices ever-downward.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.